Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
D000480:Alkynes / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000480:Alkynes; D000970:Antineoplastic Agents; D002219:Carbamates; D003510:Cyclohexanes